Actinium Pharmaceuticals Inc (ATNM)

Trade ATNM now with
11/1/2018 9:15:35 AM Actinium: Meeting Presence To Include Oral Presentation Of Feasibility,Results Of Iomab-B Pivotal Phase 3 SIERRA Trial
10/30/2018 5:09:09 PM Actinium CD33 Program To Focus On Actimab-MDS Pivotal Trial
10/1/2018 8:02:50 AM Actinium Launches Iomab-ACT Program Offering Targeted Lymphodepletion Technology To CAR-T Industry
9/6/2018 8:04:10 AM Actinium Appoints Robert Daly As VP, Head Of Clinical Operations
7/17/2018 5:31:25 PM Actinium Appoints Members Of Its Nuclear Medicine Clinical Advisory Board
6/28/2018 8:01:34 AM Actinium Begins Clinical Trial To Study Effect Of Actimab-A On Minimal Residual Disease In Postremission AML Patients
6/26/2018 8:05:31 AM Actinium Pharma Announces Dosing Of 38th Patient And 25% Enrollment In Iomab-B Pivotal SIERRA Trial
6/13/2018 8:01:41 AM Actinium Reports Treatment Of First Patient In Novel Combination Trial Of Actimab-A Plus CLAG-M
5/1/2018 7:31:52 AM Actinium Adds Jeffrey Chell To Board
4/18/2018 7:31:49 AM Actinium Strengthens Targeted Myeloablation Focused Clinical Development Team
4/11/2018 7:31:34 AM Actinium Pharma To Showcase Capabilities Of Its AWE Technology Platform In Developing Biobetters
3/28/2018 8:02:18 AM Actinium Announces Collaborative Research Partnership With Astellas Leveraging Actinium’s AWE Platform Tech
3/14/2018 7:31:34 AM Actinium Pharma Appoints Jehan Rowlands As VP, Head Of Regulatory Affairs
3/13/2018 7:33:01 AM Actinium Reports FDA Clearance Of IND For Phase 1 Trial Of Actimab-A In Combination With CLAG-M
2/27/2018 7:31:28 AM Actinium Activates Sixteen Clinical Trial Sites In Pivotal Phase 3 SIERRA Trial
2/26/2018 10:05:18 AM Actinium Reiterates Expiration Date Of March 2, 2018 At 5:00 PM ET And Amendment To Pricing Terms Of Rights Offering
2/22/2018 7:33:07 AM Actinium Announces Commencement Of Rights Offering Subscription Period
2/20/2018 7:32:58 AM Actinium Announces Product Showcase And Other Visibility Extending Activities At The BMT Tandem Meetings